Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Direct thrombin inhibitors.

Michael S Chen1, A Michael Lincoff

  • 1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

Current Cardiology Reports
|July 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

Cardiovascular Regulatory Science: Accelerating the Path from Bench to Bedside.

American heart journal·2026
Same author

A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.

The lancet. Diabetes & endocrinology·2026
Same author

Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.

Lancet (London, England)·2026
Same author

Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials.

Diabetes, obesity & metabolism·2026
Same author

Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.

Diabetes care·2026
Same journal

Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.

Current cardiology reports·2026
Same journal

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code.

Current cardiology reports·2026
Same journal

Diagnosis and Management of Loeys-Dietz Syndrome: Evidence Gaps and Future Directions.

Current cardiology reports·2026
Same journal

Correction: Heart Disease in Older Women: Unique Challenges in Diagnosis and Management.

Current cardiology reports·2026
Same journal

Beyond the ICD: Navigating Ventricular Tachycardia Suppression Strategies in the Modern Era.

Current cardiology reports·2026
Same journal

Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics.

Current cardiology reports·2026
See all related articles

Direct thrombin inhibitors (DTIs) offer advantages over unfractionated heparin (UFH) in cardiovascular treatments. Clinical trials are exploring their use, particularly bivalirudin, in percutaneous coronary intervention (PCI) and acute coronary syndromes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Direct thrombin inhibitors (DTIs) represent a novel therapeutic class with theoretical advantages over unfractionated heparin (UFH).
  • Unlike UFH, DTIs do not activate platelets, lack circulating inhibitors, and bind to both free and clot-bound thrombin.
  • These properties have driven clinical investigations across various cardiovascular indications.

Purpose of the Study:

  • To evaluate the role of DTIs, specifically bivalirudin, as an adjunct therapy in cardiovascular interventions.
  • To assess the efficacy and safety of bivalirudin compared to UFH in percutaneous coronary intervention (PCI).

Main Methods:

  • The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial is a key study.

Related Experiment Videos

  • Bivalirudin with provisional abciximab was compared against UFH with planned abciximab in PCI patients.

    • Main Results:

    • Bivalirudin demonstrated equivalence to UFH in terms of ischemic endpoints during PCI.
    • Bivalirudin was associated with a significant reduction in bleeding events compared to UFH.

    Conclusions:

    • Bivalirudin is a viable alternative to UFH in PCI, offering comparable efficacy with improved safety.
    • Ongoing trials will further define the role of bivalirudin in primary PCI for STEMI and ACS with an early invasive strategy.